HAPLOIDENTICAL STEM CELL TRANSPLANTATION
Clinical trials for HAPLOIDENTICAL STEM CELL TRANSPLANTATION explained in plain language.
Never miss a new study
Get alerted when new HAPLOIDENTICAL STEM CELL TRANSPLANTATION trials appear
Sign up with your email to follow new studies for HAPLOIDENTICAL STEM CELL TRANSPLANTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for sickle cell: drug combo aims to boost transplant success
Disease control Recruiting nowThis study tests whether adding the drug ruxolitinib to a standard stem cell transplant regimen can lower the chance of transplant failure in children and young adults with severe sickle cell disease. About 24 participants aged 12-45 will receive a transplant from a half-matched …
Matched conditions: HAPLOIDENTICAL STEM CELL TRANSPLANTATION
Phase: PHASE1, PHASE2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New drug aims to stop immune attack after stem cell transplants
Disease control Recruiting nowThis study tests a new drug called BPC2001 to prevent acute graft-versus-host disease (aGVHD) in people receiving a stem cell transplant from a half-matched donor. aGVHD is a serious condition where donor immune cells attack the patient's body. The trial includes 50 adults with b…
Matched conditions: HAPLOIDENTICAL STEM CELL TRANSPLANTATION
Phase: PHASE2 • Sponsor: BioPhoenix Co., Ltd. • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC